Alkermes (NASDAQ: ALKS)recently surprised investors with disappointing news: the Food and Drug Administration's refusal to review its lead drug candidate. The decision casts a shadow over the future for ALKS-5461, a once-promising drug for major depression. Will Alkermes be able to convince the FDA to change its mind?
Alkermes Has Some Decisions to Make
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться